Sangamo Therapeutics (NASDAQ:SGMO) added ~11% on Monday after Wedbush Securities upgraded the genomic medication firm to Outperform from Impartial, noting a current knowledge readout for the corporate’s Fabry illness candidate ST-920.

Saying up to date knowledge from its Part 1/2 STAAR medical examine, Sangamo (SGMO) stated final week that the gene remedy, also referred to as isaralgagene civaparvovec, led to medical profit in sufferers with Fabry illness, a genetically pushed metabolic dysfunction.

“General, we discover the up to date STAAR outcomes help development into Ph3 given ST-920’s efficacy and security throughout sufferers with differing severity, levels of organ impairment” and their standing in enzyme substitute remedy (ERT), Wedbush analyst Andreas Argyrides wrote.

The analyst additionally pointed to the medical maintain on 4D Molecular Therapeutics’s (FDMT) Fabry illness candidate 4D-310 and highlighted AVROBIO’s (AVRO) choice to deprioritize its Fabry illness program.

Argyrides known as a current Freeline Therapeutics’ (FRLN) knowledge readout for its Fabry candidate FLT190 “uncompetitive.”

“…we predict all indicators level to ST-920 because the frontrunning gene remedy candidate for Fabry,” Argyrides added, elevating the value goal on Sangamo (SGMO) to $16 from $4 per share.

Nonetheless, In search of Alpha contributor Avisol Capital Companions issued a Maintain score on Sangamo (SGMO) early this month, noting that FLT190 continues to be at an early stage of improvement and “we cannot see pivotal knowledge for some time.”